论文部分内容阅读
检测了４２例重症肌无力（ＭＧ）患者周围血单个核细胞（ＰＢＭＣ）白细胞介素－２（ＩＬ－２）活性及血清可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）水平，重点观察了１４例ＭＧ患者在糖皮质激素（ＧＣ）治疗后ＩＬ－２活性及ｓＩＬ－２Ｒ水平变化。结果显示，ＭＧ患者ＰＢＭＣＩＬ－２活性显著低于正常对照组，而血清ｓＩＬ－２Ｒ水平显著高于正常对照组，且ＭＧ患者ＩＬ－２活性与ｓＩＬ－２Ｒ水平之间呈显著负相关；应用ＧＣ治疗后，ＩＬ－２活性显著升高，ｓＩＬ－２Ｒ水平显著下降。提示ＭＧ患者ＩＬ－２活性变化与ｓＩＬ－２Ｒ水平密切相关，ＧＣ可通过影响ＩＬ－２活性及ｓＩＬ－２Ｒ水平而发挥免疫治疗作用。
Peripheral blood mononuclear cells (PBMCs), interleukin-2 (IL-2) activity and serum soluble interleukin-2 receptor (sIL-2R) levels were measured in 42 patients with myasthenia gravis (MG) Changes of IL-2 activity and sIL-2R levels in 14 MG patients after glucocorticoid treatment. The results showed that the activity of PBMCIL-2 in MG patients was significantly lower than that in normal control group, but the serum sIL-2R level was significantly higher than that in normal control group. There was a significant negative correlation between IL-2 activity and sIL-2R level in MG patients. After treatment, IL-2 activity was significantly increased, sIL-2R levels decreased significantly. It is suggested that the change of IL-2 activity in MG patients is closely related to the level of sIL-2R. GC can play an immunotherapy role by affecting the activity of IL-2 and the level of sIL-2R.